Mitochondrial‑DNA‑associated TLR9 signalling is a potential serological biomarker for non‑small cell lung cancer

Lai,Yu‑Heng; Liu,Hao‑Yun; Huang,Chun‑Yao; Chau,Yat‑Pang; Wu,Semon

doi:10.3892/or.2018.6855

Mitochondrial‑DNA‑associated TLR9 signalling is a potential serological biomarker for non‑small cell lung cancer

Authors:
- Yu‑Heng Lai
- Hao‑Yun Liu
- Chun‑Yao Huang
- Yat‑Pang Chau
- Semon Wu
View Affiliations

Affiliations: Department of Chemistry, Chinese Culture University, Taipei 11114, Taiwan, R.O.C., Institute of Anatomy and Cell Biology, School of Medicine, National Yang Ming University, Taipei 112, Taiwan, R.O.C., Department of Pulmonary and Critical Care, Taipei Tzu Chi Hospital, The Buddhist Tzu Chi Medical Foundation, New Taipei 231, Taiwan, R.O.C., Department of Medicine, Mackay Medical College, New Taipei 252, Taiwan, R.O.C., Department of Life Science, Chinese Culture University, Taipei 11114, Taiwan, R.O.C.
Published online on: November 9, 2018 https://doi.org/10.3892/or.2018.6855
Pages: 999-1006

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mitochondrial (mt) DNA has been long suggested to contribute to carcinogenesis, and a variety of mutations in mtDNA have been confirmed to be related to various early stages of cancers; these data revealed that the detection of mtDNA in clinical samples may be a promising approach for cancer diagnosis. In the present study, the serum mtDNA in healthy donors and groups of patients with cancer was detected. It was revealed that patients with lung cancer without metastasis had more mtDNA in serum compared to patients with metastasis. Moreover, TLR9‑associated signalling was activated in vitro after treatment with a synthetic CpG oligodeoxyribonucleotide (ODN) called ODN‑M362. In addition, our data revealed that TLR9 and its adaptor protein, MyD88, were induced by ODN‑M362 in a dose‑dependent manner. A human cytokine array to evaluate stimulation of cytokine secretion by ODN‑M362 was also used. Our findings may identify the role that TLR9 and mtDNA play in lung cancer progression and metastasis.

View Figures

View References

1	Wallace DC: Mitochondrial DNA sequence variation in human evolution and disease. Proc Natl Acad Sci USA. 91:8739–8746. 1994. View Article : Google Scholar : PubMed/NCBI
2	Liu B, Du Q, Chen L, Fu G, Li S, Fu L, Zhang X, Ma C and Bin C: CpG methylation patterns of human mitochondrial DNA. Sci Rep. 6:234212016. View Article : Google Scholar : PubMed/NCBI
3	Michl L and Shumacher HB Jr: Pulmonary valvular incompetence in growing animals. Surgery. 73:412–415. 1973.PubMed/NCBI
4	Cavalli LR and Liang BC: Mutagenesis, tumorigenicity, and apoptosis: Are the mitochondria involved? Mutat Res. 398:19–26. 1998. View Article : Google Scholar : PubMed/NCBI
5	Parrella P, Xiao Y, Fliss M, Sanchez-Cespedes M, Mazzarelli P, Rinaldi M, Nicol T, Gabrielson E, Cuomo C, Cohen D, et al: Detection of mitochondrial DNA mutations in primary breast cancer and fine-needle aspirates. Cancer Res. 61:7623–7626. 2001.PubMed/NCBI
6	Hosgood HD III, Liu CS, Rothman N, Weinstein SJ, Bonner MR, Shen M, Lim U, Virtamo J, Cheng WL, Albanes D, et al: Mitochondrial DNA copy number and lung cancer risk in a prospective cohort study. Carcinogenesis. 31:847–849. 2010. View Article : Google Scholar : PubMed/NCBI
7	Jakupciak JP, Maragh S, Markowitz ME, Greenberg AK, Hoque MO, Maitra A, Barker PE, Wagner PD, Rom WN, Srivastava S, et al: Performance of mitochondrial DNA mutations detecting early stage cancer. BMC Cancer. 8:2852008. View Article : Google Scholar : PubMed/NCBI
8	Galluzzi L, Kepp O and Kroemer G: Mitochondria: Master regulators of danger signalling. Nat Rev Mol Cell Biol. 13:780–788. 2012. View Article : Google Scholar : PubMed/NCBI
9	Goulopoulou S, Matsumoto T, Bomfim GF and Webb RC: Toll-like receptor 9 activation: A novel mechanism linking placenta-derived mitochondrial DNA and vascular dysfunction in pre-eclampsia. Clin Sci. 123:429–435. 2012. View Article : Google Scholar : PubMed/NCBI
10	Underhill DM, Ozinsky A, Smith KD and Aderem A: Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages. Proc Natl Acad Sci USA. 96:14459–14463. 1999. View Article : Google Scholar : PubMed/NCBI
11	Latz E, Visintin A, Espevik T and Golenbock DT: Mechanisms of TLR9 activation. J Endotoxin Res. 10:406–412. 2004. View Article : Google Scholar : PubMed/NCBI
12	Nishiya T, Kajita E, Miwa S and Defranco AL: TLR3 and TLR7 are targeted to the same intracellular compartments by distinct regulatory elements. J Biol Chem. 280:37107–37117. 2005. View Article : Google Scholar : PubMed/NCBI
13	Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, Brohi K, Itagaki K and Hauser CJ: Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 464:104–107. 2010. View Article : Google Scholar : PubMed/NCBI
14	Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, et al: A Toll-like receptor recognizes bacterial DNA. Nature. 408:740–745. 2000. View Article : Google Scholar : PubMed/NCBI
15	Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, Lien E, Nilsen NJ, Espevik T and Golenbock DT: TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol. 5:190–198. 2004. View Article : Google Scholar : PubMed/NCBI
16	Akira S and Hoshino K: Myeloid differentiation factor 88-dependent and -independent pathways in toll-like receptor signaling. J Infect Dis. 187 Suppl 2:S356–S363. 2003. View Article : Google Scholar : PubMed/NCBI
17	Vollmer J: TLR9 in health and disease. Int Rev Immunol. 25:155–181. 2006. View Article : Google Scholar : PubMed/NCBI
18	Berger R, Fiegl H, Goebel G, Obexer P, Ausserlechner M, Doppler W, Hauser-Kronberger C, Reitsamer R, Egle D, Reimer D, et al: Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Sci. 101:1059–1066. 2010. View Article : Google Scholar : PubMed/NCBI
19	Väisänen MR, Väisänen T, Jukkola-Vuorinen A, Vuopala KS, Desmond R, Selander KS and Vaarala MH: Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors. Prostate. 70:817–824. 2010. View Article : Google Scholar : PubMed/NCBI
20	Kauppila JH, Takala H, Selander KS, Lehenkari PP, Saarnio J and Karttunen TJ: Increased Toll-like receptor 9 expression indicates adverse prognosis in oesophageal adenocarcinoma. Histopathology. 59:643–649. 2011. View Article : Google Scholar : PubMed/NCBI
21	Sandholm J and Selander KS: Toll-like receptor 9 in breast cancer. Front Immunol. 5:3302014. View Article : Google Scholar : PubMed/NCBI
22	Krieg AM: Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene. 27:161–167. 2008. View Article : Google Scholar : PubMed/NCBI
23	Wooldridge JE and Weiner GJ: CpG DNA and cancer immunotherapy: Orchestrating the antitumor immune response. Curr Opin Oncol. 15:440–445. 2003. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^ΔΔ^C^T method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Lo YM, Tein MS, Lau TK, Haines CJ, Leung TN, Poon PM, Wainscoat JS, Johnson PJ, Chang AM and Hjelm NM: Quantitative analysis of fetal DNA in maternal plasma and serum: Implications for noninvasive prenatal diagnosis. Am J Hum Genet. 62:768–775. 1998. View Article : Google Scholar : PubMed/NCBI
26	Vecchiarelli A, Retini C, Casadevall A, Monari C, Pietrella D and Kozel TR: Involvement of C3a and C5a in interleukin-8 secretion by human polymorphonuclear cells in response to capsular material of Cryptococcus neoformans. Infect Immun. 66:4324–4330. 1998.PubMed/NCBI
27	Waugh DJ and Wilson C: The interleukin-8 pathway in cancer. Clin Cancer Res. 14:6735–6741. 2008. View Article : Google Scholar : PubMed/NCBI
28	Arango Duque G and Descoteaux A: Macrophage cytokines: Involvement in immunity and infectious diseases. Front Immunol. 5:4912014.PubMed/NCBI
29	Aldinucci D and Colombatti A: The inflammatory chemokine CCL5 and cancer progression. Mediators Inflamm. 2014:2923762014. View Article : Google Scholar : PubMed/NCBI
30	Lee MS, Kim HP, Kim TY and Lee JW: Gefitinib resistance of cancer cells correlated with TM4SF5-mediated epithelial-mesenchymal transition. Biochim Biophys Acta. 1823:514–523. 2012. View Article : Google Scholar : PubMed/NCBI
31	Lee H, Lee JH, Kim DC, Hwang I, Kang YN, Gwon GJ, Choi IJ and Kim S: Is mitochondrial DNA copy number associated with clinical characteristics and prognosis in gastric cancer? Asian Pac J Cancer Prev. 16:87–90. 2015. View Article : Google Scholar : PubMed/NCBI
32	Qu F, Chen Y, Wang X, He X, Ren T, Huang Q, Zhang J, Liu X, Guo X, Gu J and Xing J: Leukocyte mitochondrial DNA content: A novel biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Carcinogenesis. 36:543–552. 2015. View Article : Google Scholar : PubMed/NCBI
33	Weerts MJ, Sieuwerts AM, Smid M, Look MP, Foekens JA, Sleijfer S and Martens JW: Mitochondrial DNA content in breast cancer: Impact on in vitro and in vivo phenotype and patient prognosis. Oncotarget. 7:29166–29176. 2016. View Article : Google Scholar : PubMed/NCBI
34	Pao W and Chmielecki J: Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer. 10:760–774. 2010. View Article : Google Scholar : PubMed/NCBI
35	Liu B, Su Y, Li T, Yuan W, Mo X, Li H, He Q, Ma D and Han W: CMTM7 knockdown increases tumorigenicity of human non-small cell lung cancer cells and EGFR-AKT signaling by reducing Rab5 activation. Oncotarget. 6:41092–41107. 2015. View Article : Google Scholar : PubMed/NCBI
36	Droemann D, Albrecht D, Gerdes J, Ulmer AJ, Branscheid D, Vollmer E, Dalhoff K, Zabel P and Goldmann T: Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res. 6:12005. View Article : Google Scholar : PubMed/NCBI
37	Damiano V, Caputo R, Bianco R, D'Armiento FP, Leonardi A, De Placido S, Bianco AR, Agrawal S, Ciardiello F and Tortora G: Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors. Clin Cancer Res. 12:577–583. 2006. View Article : Google Scholar : PubMed/NCBI
38	Han R, Wang X, Zhong D, Zhao J, Chen Z, Sun L, Wang J and Zhang J: Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650. Zhongguo Fei Ai Za Zhi. 15:689–693. 2012.(In Chinese). PubMed/NCBI